According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +11.36% and -86.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

On Nov. 21, shares of CRISPR Therapeutics(NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.47, marking a -0.55% move from the previous day. This change lagged the S&P 500's 1.1% gain on the day. Meanwhile, the Dow ...